Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decrease in high density lipoprotein cholesterol (HDL-C) levels following gemfibrozil therapy

A G Lacko1, B J Kudchodkar, W W Loney

  • 1Department of Molecular Biology, University of North Texas Health Science Center, Fort Worth, USA.

Clinical Chemistry and Laboratory Medicine
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning-assisted radiomics facilitates multimodal prognostication for personalized treatment strategies in low-grade glioma.

Scientific reports·2023
Same author

A machine learning approach for the factorization of psychometric data with application to the Delis Kaplan Executive Function System.

Scientific reports·2021
Same author

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.

ESMO open·2021
Same author

Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2019
Same author

MicroRNAs 143 and 150 in whole blood enable detection of T-cell immunoparalysis in sepsis.

Molecular medicine (Cambridge, Mass.)·2018
Same author

Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.

Infection·2018
Same journal

Fish-shaped erythrocytes and pincer cells co-occur in distinct hematological disorders and are associated with anemia severity.

Clinical chemistry and laboratory medicine·2026
Same journal

Artificial general intelligence and the clinical laboratory: a paradigm shift toward Lab 2.0.

Clinical chemistry and laboratory medicine·2026
Same journal

Addressing property and unit discordance in laboratory interoperability: the role of NPU as a governance layer.

Clinical chemistry and laboratory medicine·2026
Same journal

Ethical evaluation of reflex and reflective testing in conformity with ISO 15189:2022 at the value-based laboratory medicine era.

Clinical chemistry and laboratory medicine·2026
Same journal

Emerging blood-based diagnostic strategies for tuberculosis.

Clinical chemistry and laboratory medicine·2026
Same journal

Homocitrulline and 3-year mortality in older hospitalised adults: an exploratory study.

Clinical chemistry and laboratory medicine·2026
See all related articles

Gemfibrozil therapy variably impacts high density lipoprotein cholesterol. Some individuals show impaired conversion of triglyceride-rich lipoproteins, leading to poor or negative responses to this cholesterol-lowering treatment.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Lipid Metabolism

Background:

  • Gemfibrozil therapy is used to manage lipid disorders.
  • Previous studies showed a mean 20% increase in high density lipoprotein cholesterol (HDL-C) with gemfibrozil.
  • However, the response to gemfibrozil therapy is highly variable among individuals.

Purpose of the Study:

  • To investigate the reasons behind the variable response to gemfibrozil therapy.
  • To explore the relationship between plasma lipid changes and individual responses to gemfibrozil.
  • To identify potential mechanisms underlying poor or negative HDL-C response to gemfibrozil.

Main Methods:

  • Continuation of studies on gemfibrozil therapy effects.
  • Analysis of high density lipoprotein cholesterol (HDL-C) levels before and after 12 weeks of therapy.

Related Experiment Videos

  • Examination of plasma lipid profiles and correlational relationships.

    • Main Results:

    • Despite a mean HDL-C increase of 20%, five out of 27 subjects experienced lower HDL-C levels post-therapy.
    • Observed changes in plasma lipids suggest variability in lipoprotein metabolism.
    • Correlational analyses indicated potential issues in triglyceride-rich lipoprotein conversion.

    Conclusions:

    • The conversion of triglyceride-rich lipoprotein components into high density lipoprotein may be impaired in non-responders.
    • This impairment could explain the poor or negative responses observed in some patients undergoing gemfibrozil therapy.
    • Further research is needed to elucidate the precise mechanisms of variable HDL-C response to gemfibrozil.